Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 580

1.

The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.

Stone NN, Crawford ED, Skouteris VM, Arangua P, Metsinis PM, Lucia MS, La Rosa FG, Werahera PN.

J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204. [Epub ahead of print]

PMID:
30835628
2.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2018 Oct - Dec;52(5-6):349-357. doi: 10.1080/21681805.2018.1522372. Epub 2019 Jan 9.

PMID:
30624128
3.

Detection of Cryptococcus DNA by Metagenomic Next-generation Sequencing in Symptomatic Cryptococcal Antigenemia.

Ramachandran PS, Cresswell FV, Meya DB, Langelier C, Crawford ED, DeRisi JL, Boulware DR, Wilson MR.

Clin Infect Dis. 2019 May 17;68(11):1978-1979. doi: 10.1093/cid/ciy1024. No abstract available.

PMID:
30535266
4.

Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults.

Langelier C, Kalantar KL, Moazed F, Wilson MR, Crawford ED, Deiss T, Belzer A, Bolourchi S, Caldera S, Fung M, Jauregui A, Malcolm K, Lyden A, Khan L, Vessel K, Quan J, Zinter M, Chiu CY, Chow ED, Wilson J, Miller S, Matthay MA, Pollard KS, Christenson S, Calfee CS, DeRisi JL.

Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12353-E12362. doi: 10.1073/pnas.1809700115. Epub 2018 Nov 27.

5.

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET.

Integr Cancer Ther. 2018 Dec;17(4):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5.

6.

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G.

BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2.

PMID:
30288918
7.

Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.

Zinter MS, Dvorak CC, Mayday MY, Iwanaga K, Ly NP, McGarry ME, Church GD, Faricy LE, Rowan CM, Hume JR, Steiner ME, Crawford ED, Langelier C, Kalantar K, Chow ED, Miller S, Shimano K, Melton A, Yanik GA, Sapru A, DeRisi JL.

Clin Infect Dis. 2019 May 17;68(11):1847-1855. doi: 10.1093/cid/ciy802.

PMID:
30239621
8.

Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ, Klotz L.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38. doi: 10.1038/s41391-018-0079-0. Epub 2018 Aug 21. Review.

9.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
10.

Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison.

Skouteris VM, Crawford ED, Mouraviev V, Arangua P, Metsinis MP, Skouteris M, Zacharopoulos G, Stone NN.

Rev Urol. 2018;20(1):19-25. doi: 10.3909/riu0785.

11.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
12.

Editorial Comment.

Crawford ED.

J Urol. 2018 Aug;200(2):343. doi: 10.1016/j.juro.2018.03.136. Epub 2018 Apr 19. No abstract available.

PMID:
29679579
13.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J.

Urol Oncol. 2018 Jun;36(6):310.e7-310.e13. doi: 10.1016/j.urolonc.2018.03.011. Epub 2018 Apr 11.

PMID:
29655620
14.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

PMID:
29630978
15.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

PMID:
29624463
16.

The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED.

Prostate. 2018 May;78(7):506-511. doi: 10.1002/pros.23495. Epub 2018 Feb 19.

17.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED.

Ther Adv Urol. 2017 Nov 22;10(2):43-50. doi: 10.1177/1756287217738150. eCollection 2018 Feb.

18.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

19.

Fewer Recurrences with Immediate versus Delayed Intravesical Mitomycin C: A Prospective Randomized European Trial.

Wilson SS, Crawford ED.

Eur Urol. 2018 Feb;73(2):233-235. doi: 10.1016/j.eururo.2017.09.014. Epub 2017 Sep 28. No abstract available.

PMID:
28967551
20.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

Supplemental Content

Loading ...
Support Center